A simple DNA blood test can now tell doctors within four weeks whether a breast cancer treatment is actually working—and if it's not, there's time to switch to something else.
Researchers at the Institute of Cancer Research in London measured circulating tumor DNA (ctDNA)—fragments of cancer DNA that leak into the bloodstream—in blood samples from 167 patients with advanced breast cancer. They tested patients before treatment started and again after just one cycle, four weeks in.
The pattern was stark. For patients with triple negative breast cancer, those with low ctDNA before treatment had a 40% response rate. Those with higher ctDNA? Just 9.7%. After four weeks, the gap widened even more: patients whose ctDNA became undetectable kept their cancer stable for over a year. Those whose ctDNA remained detectable saw their cancer progress in 4.3 months.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News Detox"By analyzing circulating tumor DNA in blood samples, we identified a clear link between these levels and how well patients responded to therapy," said Dr. Iseult Browne, the study's lead author. "This supports using ctDNA as a non-invasive biomarker for predicting outcomes and monitoring treatment response."
What makes this genuinely useful is the timing. Waiting months to see if a treatment is working means months of side effects from a drug that might not help. This test compresses that window to four weeks—early enough that doctors can pivot to a different therapy or enroll patients in clinical trials testing newer options instead of staying locked into a failing approach.
The researchers stress this isn't just theoretical. Trials are already underway to test whether adapting treatment based on these early blood tests actually improves how long patients survive and how well they live. Prof. Nicholas Turner, a co-author, noted that while this study focused on advanced breast cancer, the same logic could work for early-stage cases too—making treatment decisions faster and more personalized across the board.
The real shift here is moving from "let's try this and see" to "let's check if this is working and adjust accordingly." For people already dealing with a cancer diagnosis, that's not just progress. It's precision.
